Please login to the form below

epigenetics

This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.

RNA-focused biotech Storm Therapeutics raises extra £14m

First set up in 2015 by epigenetics and RNA specialists Professor Tony Kouzarides and Professor Eric Miska, the Cambridge-based company has a pipeline of early-stage molecules in development in ... world-leading company harnessing the power of RNA

Latest news

Researchers reverse Alzheimer’s memory loss in mice

The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... The researchers found that the loss of glutamate receptors resulted from an epigenetic process
GSK: we won’t be splitting up any time soon

Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.
AstraZeneca to explore link between epigenetics and respiratory diseases

Epigenetics are changes in the expression of genes attributed to lifestyle factors affecting the body, but do not alter the DNA sequence. ... To date, research into epigenetics has been largely focused on cancer, but the collaborators believe it houses
Biogen buys into Rodin's Alzheimer's candidate

And may acquire the epigenetics-focused Massachusetts firm. Biogen has signed a deal with Atlas Venture-backed Rodin Therapeutics that could result in the acquisition of the Alzheimer's disease-focused ... Biogen has its own research programme in
Novartis' Farydak gets nod for myeloma in Europe

Novartis says its approval marks "the first time an HDAC inhibitor with epigenetic activity is available in the EU," providing a much-needed additional line of therapy for patients with aggressive

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at
Deal Watch November 2016

licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
Deal Watch January 2016

Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
Deal Watch October 2015

Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
Pharma deals in August 2015

This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

Professor Thomas Cech joins Storm Therapeutics

mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
Storm Therapeutics bolsters its team

As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
Storm Therapeutics strengthens its board

RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
Rubius Therapeutics strengthens senior team

He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
Paul Stockdale joins Oxford BioDynamics as CFO

A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Account Executive: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director: Salary TBC

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Senior Medical Writer: Salary TBC

Account Supervisor: Salary TBC

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Medical Writer – Very Flexible Working – Surrey: Negotiable

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Graduate Scientific Editor: DOE

Subscribe to our email news alerts

PMHub

Add my company

Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail: We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?: Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Strengthening business competition and reducing anti-competitive practices: How the CMA is tackling high prices for essential drugs...